Treatment of Coronary Artery Disease: Sisyphus’ Work? by Umans, V.A.W.M. (Victor) et al.
Treatment of Coronary Artery Disease: Sisyphus' Work? 
V.A.W.M. UMANS, M.D., B.H. STRAUSS, M.D., PH.D., and P.W. SERRUYS, M.D., PH.D. 
From the Catheterisation Laboratory, Thoraxcenter, Academical Hospital Dijkzigt, Rotterdam, The Netherlands 
A 37-year-old male with a hyperlipidemia type Ila underwent three conventional percutaneous translu- 
minal coronary angioplasty procedures and three surgical revascularizations for  recurrent restenosis 
of the saphenous vein bypass graft, Despite these interventions, a long-term success was never 
achieved. Stent implantation at the site of a rerestenosis was successful. However, a second stent 
implantation to  prevent further progression of another previously nonmanipulated atheromateous le- 
sion resulted in a stenosis within the stent for which a new surgical intervention was indicated. A t  
surgery the stented graft was replaced by a fresh venous graft. The partly removed venous graft 
containing the two stents provides a unique opportunity to study the long-term histologic effects of 
intravascular stenting. ( J  Interven Cardiol 1992; 55-14) 
Introduction 
Percutaneous transluminal coronary angio- 
plasty (PTCA) has become the treatment of 
choice for most patients with symptomatic single 
vessel disease and selected multivessel disease. 
Another rapidly growing indication for PTCA 
consists of patients with recurrent angina after 
coronary bypass surgery, who may undergo 
either dilatation of a native coronary artery steno- 
sis or of a bypass graft stenosis. However, in ap- 
proximately 20%-40% of patients, evidence of 
myocardial ischemia reappears within 6 months 
of the dilatati~n.'-~ Restenosis rate within the by- 
pass graft is even higher than the rate observed 
in the native coronary  vessel^^.^ and remains one 
of the main limitations of this therapeutic pro- 
cedure. 
Recently, intravascular stenting for prevention 
of restenosis was introduced.6 Initial data suggest 
~ ~ ~ ~ 
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that stenting may offer an alternative treatment 
to selected patients with recurrent angina due to 
graft stenosis after previous coronary bypass 
surgery. 
This case report highlights the problems of pa- 
tient management with recurrent restenosis of sa- 
phenous vein bypass grafts after several angio- 
plasties and surgical revascularization proce- 
dures. Despite these various modes of treatment 
a long-term success was never achieved. Stent 
implantations were performed initially to treat a 
recurrent stenosis accompanied by symptoms 
and later to prevent progression of a stenosis not 
associated with symptoms. However, after 3 
months angina recurred and angiography re- 
vealed a stenosis in the second stent. Another 
surgical revascularization was indicated. Again at 
3 months, angina recurred due to a stenosis at the 
anastomosis between the two grafts. A third stent 
was successfully implanted. 
This anecdotal case gives us the opportunity to 
review the changing spectrum of pharmacological 
and interventional treatment of ischemic heart 
disease over the last decade. 
Case Report 
Clinical History. In 1977 a 37-year-old active 
smoker with a hyperlipedimia type IIa and a posi- 
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CABG = coronary artery bypass grafting; CATH = catheter; 
LAD = left anterior descending coronary artery; LIMA = 
left internal mammary artery; PTCA = percutaneous translu- 
minal coronary angioplasty: RD = diagonal branch of the left 
coronary artery; RM = marginal coronary artery: and RDP 
= descending posterior coronary artery. 
tive family history. presented with an inferior- 
myocardial infarction. Table I summarizes the 
major events in the 12-year time frame. Briefly, 
coronary angiography revealed an occlusion of 
the left anterior descending coronary artery 
(LAD) and left circumflex coronary artery. The 
marginal arteries were severely diseased. Collat- 
eralized circulation from the right coronary artery 
to the distal part of the left descending coronary 
artery was visualized. 
Despite optimal pharmacological treatment 
and intraaortic balloon pumping he remained un- 
stable and received one jump graft with four distal 
anastomoses at urgent coronary artery bypass 
grafting. 
Recovery was uneventful and the patient was 
discharged on dipyridamol and aspirin therapy. 
Repeat angiography and thallium exercise testing 
were performed 1 and 4 years later as part of an 
ongoing study of the functional result of bypass 
surgery on left ventricular (LV) function.8 At 4 
years (March 1981) angiography revealed a 70% 
stenosis of the distal anastomosis to the second 
obtuse marginal branch. Because of persistent el- 
evation of serum cholesterol, he was referred to 
our lipid clinics. Initial treatment consisted of 
colestyrarnine. An optimal dose regimen was 
never given because of nausea. Since 1988 he was 
treated with symvastatine, a HMG CoA re- 
ductase inhibitor. The resultant decrease in the 
cholesterol levels is shown in Table 2. 
In January 1982, balloon angioplasty was per- 
formed on a totally occluded venous jump graft 
for recurrent angina. Because of an extensive col- 
lateral network, the patient was spared a recur- 
rent myocardial infarction. Repeat attempts at 
surgical revascularization was not performed be- 
cause of anticipated risk exceeding those accru- 
ing to the performance of balloon angiopla~ty.'.'~ 
The occlusion was mechanically recanalized by 
means of a 0.035-inch teflon coated guidewire and 
successfully dilated, although a long nonobstruc- 
tive dissection was documented at the site of the 
dilatation. 
Recurrence of angina was noted at 2 months 
Table 2. Serum Cholesterol Level 
Cholesterol Triglyceride 
Date (mmol/L) (mmol/L) Medication 
1977 7.6 I .40 
I978 12.7 1.45 
1979 8.8 0.96 
1982 Colest yramine 
1983 9.5 1.06 
4/13/88 10.4 I .30 
41 1 8/88 8.6 I .63 
5/02/88 9.1 Colest yramine 
612 1 188 10.2 Colest yramine 
8/02/88 10.6 
10/06/88 10.8 1.66 
11/17/88 8.2 I .23 Simvastatine 
1 x 10mg 
I2/29/88 7.9 1.14 Simvastatine 
I x 20mg 
21 14/89 7.8 1.31 
4/05/89 6.8 2.29 
71 18/89 7.1 Simvastatine 
I x 30mg 
10/23/89 Simvastatine 
1 x 40 mg 
12/27/89 5.0 
Normal values; total cholesterol, 3.3-8.0 rnrnoUL; triglycer- 
ides. 0.3-1.6 mmoUL. 
4 x 4 g  
1 x 4 g  
1 x 4 g  
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follow-up. A second balloon angioplasty was con- 
sidered contraindicated because of the dissection 
flap and a surgical reintervention was recom- 
mended. At surgery (June 1982) a bypass graft 
was implanted on the proximal part of the preex- 
isting bypass. 
In November 1982, he again experienced exer- 
tional angina due to a stenosis of the anastomosis 
of the bypass on the bypass that was successfully 
dilated. 
In May 1984, a third PTCA procedure was nec- 
essary to dilate a restenosis at the anastomosis of 
the bypass on the bypass. 
In April 1988, he again became increasingly 
symptomatic despite optimal pharmacological 
treatment. This time coronary angiography dis- 
closed a total occlusion of the distal jump graft 
between the two marginal branches and a rereste- 
nosis of the bypass-jump graft anastomosis. 
With our surgical team, the decision was taken to 
perform PTCA with stent implantation. 
In September 1988, a fourth PTCA procedure 
was performed. The rerestenosis of the by- 
pass-jump graft was successfully dilated with a 
4.2-mm balloon at 12 atmospheres (atm). After 
dilatation a residual stenosis of 20%-30% was 
present and there upon a 4.5-mm diameter stent 
(Medinvent, Lausanne, Switzerland) was im- 
planted (Fig. I ) .  At 6 months angiography there 
was no recurrent stenosis but a plaque encroach- 
ing the lumen at distance of the previous im- 
planted stent was documented. To prevent fur- 
ther progression of this lesion in the single re- 
maining conduit supplying the entire heart it was 
decided to implant another stent. This asymmet- 
ric encroaching plaque was successfully reached 
and a 4.5-mm stent (Medinvent) implanted (Fig. 
2). At 4 months he presented again with unstable 
angina. At coronary angiography a severe reste- 
nosis within the second stent was found. Another 
PTCA procedure was considered inappropriate 
mainly because the single remaining stenotic by- 
pass graft was considered a main stem equivalent. 
In addition, the fibrocellular and proliferative na- 
ture of the stenosis let us foresee a high probabil- 
ity of an unfavorable short-term result. 
In July 1989, the proximal part of the jump graft 
was resected and replaced by a new venous graft. 
The left internal mammary artery (LIMA) was 
grafted distally on the jump graft and a new ve- 
Figure 1. Successful implantation of the first stent. In the 
upper panel, the pre PTCA angiogram is shown with the rere- 
stenosis in the proximal bypass graft. The lower panel shows 
the post stent implantation angiogram. 
nous graft was connected to a posterolateral 
branch. 
In December 1989 he again experienced exer- 
tional angina. Repeated coronary angiography re- 
vealed a severe proximal stenosis in the jump 
graft and a functional occlusion of the LIMA. The 
angiographic appearance of the stenosis sug- 
gested a cicatricial retraction at the site of the 
suture had occured. A fourth surgical revasculari- 
zation was considered inappropriate since the in- 
ternal mammary artery had already been used. 
Subsequently, a third stent implantation was per- 
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Figure 2. Cineangiogram of the second stent implantation procedure. (A)  The primary stenosis before stenting is shown. The first 
stent is widely patent without signs of a restenosis. After stent implantation (B) no residual stenosis is seen. (C) Three-month 
follow-up angiogram after the second stent implantation (10 months after the first stent implantation). The second stent contains 
a restenosis while the first stent is widely patent. 
formed without complications (Fig. 3) .  At 3 
months angiographic follow-up, the stent was 
patent without signs of abnormal hyperplasia. 
Histology. Data from our animal experiments 
have shown that following stent implantation 
major histologic changes occur. ’ ’ The embedded 
stent wires create a deformation and out- 
stretching of the media while the internal elastic 
membrane is interrupted. Within 48 hours after 
stent implantation massive deposition of leuco- 
cytes, platelets, erythrocytes, and fibrin, occur in 
the “dead spaces” surrounding the stent struts. 
This process in combination with the presence of 
the nondegradable wires and hemostasis at the 
site of the struts results in chemotaxis of mono- 
cytes. These monocytes subsequently transform 
into macrophages, which act as scavengers and 
are ultimately transformed into foam cells. At 4 
weeks a neointima composed of disorganized lay- 
ers of myofibrillar cells covers the stent wires. 
At the luminal side two distinct layers of smooth 
muscle layers are present, one in a circular orien- 
tation immediately below the endothelium and a 
deeper layer in a longitudinal orientation. Finally, 
complete coverage with endothelial cells will 
occur. After 3 months, a more extensive neoin- 
tima has formed with only a small area adjacent to 
the stent wires containing leucocytes and cellular 
debris. 
Histologic cross section of a porcine coronary 
artery 1 week after stent implantation thus re- 
veals a combination of thrombotic and myoproli- 
ferative process, which was initiated in the “dead 
spaces” near the stent struts. In the stented ve- 
nous bypass graft, the spaces directly around the 
stent struts become filled with depositions of leu- 
cocytes, macrophages, and fibrin that were all 
attracted by chemotactical forces. During forma- 
tion of the neointima these “dead spots” are 
burled and become triangular in shape. We be- 
lieve that in these triangular spaces the mystery 
of restenosis following stent implantation may be 
found. Therefore in this report, named after an 
ancient Grecian myth ,  we selected the name 
“Bermuda Triangle” for these regions because 
these “dead spaces” may play the pivotal role in 
stent induced restenosis. 
Light microscopic examination of the stented 
human venous bypass graft of our patient showed 
the same histologic changes as seen in pigs. The 
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Figure 3. Cineangiogram of the third stent implantation. Frames A and B show the stenosis before and after stenting. Frame C 
shows the 3-month follow-up result. 
first stent was completely covered by a smooth 
endothelial lining and the neointima consists of a 
few layers of elongated smooth cells with in- 
terpersed collagen and some elastin fibers (Fig. 
4). In the vicinity of the stent wires, now seen as 
voids, necrotic tissue is seen and only a few foam 
cells are demonstrated. 
The second stent is also completely covered by 
an endothelial lining; however, the neointima is 
less densely organized and considerably thicker 
compared with the first stent (Fig. 5) .  This neoin- 
tima is vascularized and consists of many layers 
of ill-arrayed smooth muscle cells and collagen. 
Around the voids, in the “Bermuda Triangle,” 
many leucocytes, foam cells, and elongated cells 
with lipid inclusions are found (Fig. 6). This area 
initially contained the corpse of leucocytes, 
erythrocytes, and platelets, which were phago- 
cyted by attracted macrophage that ultimately 
transformed into foam cells. 
Discussion 
Coronary artery bypass grafting (CABG) is an 
effective therapeutic treatment for symptomatic 
coronary artery disease. Although more than 80% 
of the patients become angina free, recurrence of 
symptoms occurs in approximately 5% to 10% 
of the patients annually. Repeat CABG provides 
symptomatic relief in only 60% to 70% of the pa- 
tients compared with more than 80% after the 
first CABG procedure.’ Moreover, repeat CABG 
is technically more difficult and mortality rates 
are higher than after initial operation.” 
We report our therapeutic strategy to prevent 
repeat bypass surgery in a patient with a bypass 
on a bypass.I2 Although all kind of interventional 
techniques have been applied, a long-term suc- 
cess was never achieved and two reoperations 
had to be performed. Reviewing this case history 
one can speculate whether another strategy 
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Figure 4. Histology specimen of the venous bypass graft containing the first stent 10 months after implantation. A smooth 
endothelial lining covers the neointima. which consists of a few well-arrayed layers of smooth muscle cells. 
would have resulted in a more favorable long- 
term result. Some limitations and possible alter- 
natives to the currently used strategy will be dis- 
cussed briefly. 
Should We Have Intervened More Aggressively 
on the Lipid Metabolism In This Patient? Studies 
on lipid lowering drugs in young males have 
shown cholesterol reduction has a beneficial ef- 
fect on cardiovascular risk.'.' I t  has also been 
clearly demonstrated that late coronary vein graft 
stenosis is due to progression of atherosclero- 
s i ~ . ' ~ - ' '  Regression of coronary artery lesions 
due to lipid lowering interventions has been docu- 
mented and is the subject of several ongoing 
At the initial presentation of this pa- 
tient a severe hypercholesterolemia was found. 
Initial treatment with colestyramine was unsuc- 
cessful in effectively reducing the cholesterol 
level and was accompanied by side-effects. The 
advent of a new class of cholesterol lowering 
drugs has contributed to normalize the choles- 
terol levels. In retrospect, more intense efforts 
at cholesterol lowering should have been made 
earlier. 
Today Would We Have Attempted PTCA in the 
First Place? A point of consideration is whether 
an initial PTCA procedure would have been more 
beneficial to the patient. Since 1977 the treatment 
of acute myocardial infarction and unstable an- 
gina has changed dramatically. As an alternative 
to surgical revascularization, PTCA is being at- 
tempted in many instances as an emergency inter- 
vention in patients with unstable angina and suita- 
ble coronary anatomy. Dilatation of the culprit 
stenosis has a 89% success ratio while complica- 
tion and restenosis rates are within acceptable 
limits.20 Unfortunately, at the time of his initial 
angiography we were confronted with two totally 
occluded coronary arteries. With the introduction 
of more sophisticated catheters it has been dem- 
onstrated that PTCA of totally occluded arteries 
is feasible although a high restenosis rate is ob- 
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Figure 5. Histology specimen of the venous bypass graft containing the second stent 3 months after implantation (hematoxylin- 
azofloxine staining). The neointima is vascularized and consists of many layers of ill-arrayed smooth muscle cells and collagen. 
~ e r v e d . ~ ' - ~ ~  A recent study from our institution 
shows that recanalization and dilatation of totally 
obstructed arteries in unstable patients has a fa- 
vorable clinical outcome.24 Today, in our initial 
strategy for this young man, we would con- 
template an attempt at  recanalization of the 
culprit lesion in order to avoid or to postpone 
surgery. 
Should We Have Used An Arterial Conduit In- 
stead of a Saphenous Vein Graft? Initial surgical 
revascularization was achieved by saphenous 
vein bypass grafting. Currently, long-term follow- 
up studies comparing venous grafts to internal 
mammary artery grafts demonstrate a superior 
long-term patency in mammary artery grafts over 
the vein  graft^.".'^,^^,^^ Actuarial survival com- 
parison showed superior survival with a 
LIMA-LAD graft.26 Also, the LIMA is an ob- 
vious choice in patients undergoing reoperation 
for failed vein grafts to the LAD.l5 At the last 
operation the LIMA was used as  a graft to the 
jump graft, and parts of the original venous graft 
were replaced by new venous grafts. Although 
the LIMA became occluded, the ideal revascu- 
larization procedure might have included the use 
of the left and right internal mammary artery in- 
stead of venous autogenous grafts. 
Stent: Chance of the Last Resort Or Start of a 
New Iatrogenic Era? Lastly, stenting has to be 
reviewed. Although in selected cases it appears 
to be a promising new technique several problems 
remains to be solved. The mechanism by which 
stent implantation may prevent restenosis is un- 
known. From a pathophysiological view point the 
stent may act as a scaffolding device optimizing 
the dilatation process,27 or may create a smooth 
endovascular lining reducing tubulent and lami- 
nar  resistance^.^^*^^ Several hypotheses have 
been proposed to explain the ability of the stent 
to prevent progression of atherosclerosis. Ac- 
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Figure 6. Light microscopic cross section through the “Bermuda triangle.” Hematoxylin-azofloxine staining. The voids marked 
by X originally contained the stent wires. Around the struts many foam cells and leucocytes are present. 
cording to these theories the stent may act as a 
mysterious “tissue barrier” preventing the mi- 
gration of cellular structures although no scien- 
tific proof supports this thesis. Second, the stent 
may induce ischemia in the vessel wall through 
compression and occlusion of the nutrient vasa 
vasorum and thereby limit progression of athero- 
sclerosis.2Y Finally, the stent by acting as a mac- 
roscopic screen prevents the protrusion of the 
atherosclerotic plaque into the lumen of the ves- 
 el.^' On the other hand stent-induced restenosis 
might result from damage of the internal elastic 
membrane, thereby inducing cell migration and 
proliferation . 3 ’  
At PTCA, substantial endothelial damage is in- 
duced resulting in splitting the arterial intima or 
even the media.”.” This may be the start of a 
vicious circle resulting in macrophage attraction 
and smooth muscle proliferation to form a neoin- 
tima. The presence of an intravascular stent may 
become an additional trigger for continued media- 
tor release, resulting in macrophage migration 
through the internal elastic membrane and foam 
cell f ~ r m a t i o n . ~ ’  
Histology of a Stent: An Open Window on the 
Restenosis Phenomenon. The unique pathology 
specimen retrieved from this patient at surgery 
shows the long-term effects of intravascular 
stenting, and thus contributes in our understand- 
ing of the basic process of atherosclerosis and the 
cellular events involved in this case. In the first 
stent no signs of a proliferative process was found 
while in the second stent an aggressive cell migra- 
tion and proliferation was seen. 
The cause of these later histologic features are 
unknown. We speculate that two factors may be 
important. First, the newly formed endothelium 
covering the embedded stent wires may be dys- 
functional and thus permit abnormal and exces- 
sive macrophage penetration and lipid accumula- 
tion across the endothelial barrier. Second, im- 
portant chemotactic substances may be released 
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in the “Bermuda Triangle,” presumably due to 
pressure necrosis. 
As a result of this process, the neointima in the 
second stent had become an extremely thickened 
layer mainly consisting of lipid containing cells. 
Alternatively, the histologic changes observed in 
the second stent might have started with a throm- 
botic process resulting in colonialization by myo- 
fibroblastic cells. This results in an organized 
thrombus mimicking some features of the hyper- 
plastic process. 
The major cellular difference between the two 
stents is the abundance of foam cells in conjunc- 
tion with a proliferative process resulting in inti- 
ma1 hyperplasia in the stent containing the reste- 
nosis. With electron microscopy it is clearly ap- 
parent that the monocytes are the precursor since 
these cells penetrate into the endothelial cells. 
This might be the onset of the vicious circle of 
chemotaxis, cellular attraction, foam cell trans- 
formation, and proliferation. Since the develop- 
ment of restenosis is thought partly to be related 
to hyperlipidemia, a pharmacological interven- 
tion resulting in lowering serum lipid levels might 
prevent foam cell accumulation and might be rec- 
ommended to accompany interventional tech- 
niques like PTCA or intravascular stenting. 
Lessons Learned From Stenting In This Case. It 
remains a rather interesting question why in only 
one of the two stents restenosis occurred. One 
explanation might be that the first stent was im- 
planted because of the development of reresteno- 
sis after several PTCA procedures, while the sec- 
ond was implanted into a nonmanipulated vessel 
segment containing an aggressive, proliferative 
plaque. The progression of the atheromatous pro- 
cess at the site of the second stent might have 
been too aggressive to be contained by the stent. 
Confronted with this observation we refrain from 
preventive stenting. These observations are in ac- 
cordance with the theory of Schatz30 that the 
stent may act as a sieve. In our histologic speci- 
men no signs of ischemia induced changes in the 
vessel wall were found. In contrast, the neointima 
of the second stent was highly vascularized, 
which gives no support to the thesis concerning 
restenosis prevention proposed by Williams.29 
This case report emphasizes evolution of man- 
agement with problems of integration of palliative 
interventional strategies into a chronic disease. 
Several times decisions were made when long- 
term data were not available. Although there ex- 
ists an enlarging experience with interventional 
techniques, a pharmacological approach appears 
to be a necessary adjunct to overcome the prob- 


















Gruntzig AR, King SB, Schlumpf M, et al. Long-term 
follow-up after percutaneous transluminal coronary an- 
gioplasty. N Engl J Med 1987; 316:1127-1132. 
Meier B, King SB, Gruntzig AR, et al. Repeat coronary 
angioplasty. J Am Coll Cardiol 1984; 4:463-466. 
Serruys PW, Luyten HE, Beatt KJ, et al. Incidence of 
restenosis after successful coronary angioplasty: A time- 
related phenomenon. Circulation 1988; 77:361-371. 
Cote G,  Myler RK, Stertzer SH, et al. Percutaneous 
transluminal angioplasty of stenotic coronary artery 
grafts: 5 years’ experience. J Am Coll Cardiol 1987; 
9:8-17. 
Douglas JS Jr, Gruntzig AR, King SB, et al. Percutane- 
ous transluminal coronary angioplasty in patients with 
prior coronary artery bypass surgery. J Am Coil Cardiol 
Sigwart U, Puel J,  Mirkowitch V,  et al. Intravascular 
stents to prevent occlusions and restenosis after translu- 
minal angioplasty. N Engl J Med 1987; 316:701-706. 
Urban P, Sigwart U, Golf S, et al. Intravascular stenting 
for stenosis of aortocoronary venous bypass grafts. J 
Am Coll Cardiol 1989; 13:1085-1091. 
Leaman DM, Brower RW, Meester GT, et al. Coronary 
artery atherosclerosis: Severity of the disease, severity 
of angina pectoris and compromised left ventricular 
function. Circulation 1981 ; 63(2):285-292. 
Dorros G,  Johnson WD, Tector AJ, et al. Percutaneous 
transluminal coronary angioplasty in patients with prior 
coronary artery bypass grafting. J Thorac Cardiovasc 
Surg 1984; 87: 17-26. 
Laird-Meeter K, van den Brand M,  Serruys PW. Reop- 
eration after aortocoronary bypass procedure. Br Heart 
Van der Giessen WJ, Serruys PW, Visser WJ, et al. En- 
dothelialization of intravascular stents. J Interven Car- 
diol 1988; 1:109-120. 
Serruys PW, de Feyter PJ, van den Brand M, et al. Hoe 
heroperatie te voorkomen bij een reeds bestaande by- 
pass op een coronaire bypass. Ned Tijdschr Geneeskd 
Lipid Research Clinic Program. The Lipid Research 
Clinics Coronary Primary Prevention Trial Results: 1. 
Reduction of incidence of coronary heart disease to cho- 
lesterol lowering. J Am Med Assoc 1984; 251:365-374. 
Campeau L. Atherosclerosis and late closure of aorto- 
coronary saphenous vein grafts: Sequential angiographic 
studies at 2 weeks, I year, 5 to 7 years, and 10 to 12 
years after surgery. Circulation 1983; 68(Suppl. 1I):II- 
Loop FD. Influence of internal mammary artery graft on 
10 year survival and other cardiac events. N Engl J Med 
Lytle BW. Long-term (5 to 12 years) serial studies of 
1983; 2~745-754. 




Vol. 5, No. 1, 1992 Journal of Interventional Cardiology 13 









internal mammary artery and saphanous vein coronary 
bypass grafts. J Thorac Cardiovasc Surg 1985; 
Hollman J ,  Konrad K.  Russell R,  et al. Lipid lowering 
for the prevention of recurrent stenosis following coro- 
nary angioplasty. (abstract) Circulation 1989; 74:ll-65. 
Sahni R,  Maniet AR, Voci G ,  et al. Prevention of reste- 
nosis by lovastatin. (abstract) Circulation 1989; 74:ll-65. 
Blankenhorn DH. Nessim SA. Johnson RL, et al. Bene- 
ficial effects of colestipolniacin therapy on coronary ath- 
erosclerosis and venous bypass grafts. J Am Med Assoc 
1987; 257:3233-3240. 
de Feyter PJ, Sermys PW, Soward A. et al. Coronary 
angioplasty for early post-infarction unstable angina. 
Circulation 1986; 74: 1365-1370. 
Serruys PW, Umans V,  Heyndrickx GR, et al. Elective 
PTCA of totally occluded coronary arteries not associ- 
ated with acute myocardial infarction; Short-term and 
long-term results. Eur Heart J 1985; 6:2-12. 
Dervan JP. Balm DS, Cherniles J, et al. Transluminal 
angioplasty of occluded coronary arteries: Use of a mov- 
able guide-wire system. Circulation 1983; 68:776-784. 
Holmes DR, Vlietstra RE. Reeder GS, et al. Angioplasty 
in total coronary artery occlusion. J Am Coll Cardiol 
1984: 3: 845-1349, 
Plante S. Laarman G ,  Samson M, et al. Acute complica- 
tions of PTCA for chronic total occlusion. (abstract) J 










33 .  
lvert T. Angiographic studies of internal mammary ar- 
tery grafts 1 1 years after coronary artery bypass grafting. 
J Thorac Cardiovasc Surg 1988; 96:l-12. 
Okies JE. The left internal mammary artery: The graft 
of choice. Circulation 1984; 7O(Suppl. I):I-213-221. 
Sermys PW, Juilliere Y, Bertrand ME, et al. Additional 
improvement of stenosis geometry in human coronary 
arteries by stenting after balloon dilatation. Am J Cardiol 
Puel J. Juilliere Y, Bertrand ME, et al. Early and late 
assessment in stenosis geometry after coronary arterial 
stenting. Am J Cardiol 1988; 61546-553. 
Williams JK, Armstong ML, Heistad DD. Vasa vasorum 
in atherosclerotic coronary arteries: Response to vaso- 
active stimuli and regression of atherosclerosis. Circ Res 
1988; 6215 15-523. 
Schatz RA. A view of vascular stents. Circulation 1989; 
79:445-457. 
Sermys PW, Beatt KJ, van der Giessen WJ. Stenting 
of coronary arteries. Are we sorcerer’s apprentice? Eur 
Heart J 1989; 10:774-782. 
Block PC, Myler RK, Stertzer S, et al. Morphology after 
transluminal angioplasty in human beings. N Engl J Med 
Essed CE, van den Brand M, Becker AE. Transluminal 
coronary angioplasty and early restenosis: Fibrocellular 
occlusion after wall laceration. Br Heart J 1983; 
49:393-3%. 
1988; 6 I :7 1G-76G. 
1981; 305~382-384. 
14 Journal of lnterventional Cardiology Vol. 5 ,  No. I ,  1992 
